Calcitonin gene-related peptide

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Cal

Retrieved on: 
Wednesday, November 22, 2023

A recent market research study (n=150) of Neurologists, Headache Specialists and Primary Care Physicians revealed that 93% of clinicians treating migraine have moderate to extremely high unmet needs for alternatives to triptan therapy.2 Clinicians stated their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use.

Key Points: 
  • A recent market research study (n=150) of Neurologists, Headache Specialists and Primary Care Physicians revealed that 93% of clinicians treating migraine have moderate to extremely high unmet needs for alternatives to triptan therapy.2 Clinicians stated their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use.
  • ELYXYB’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • In clinical studies, patients treated with ELYXYB® demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in nearly 50% of patients.
  • Approximately 34% of patients were pain free at two hours.3 Notably, these data are well differentiated from two other new oral migraine medications of a different class, calcitonin gene-related peptide (CGRP) receptor antagonists.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Thursday, October 19, 2023

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Thursday, October 19, 2023

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

Retrieved on: 
Tuesday, September 12, 2023

PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution).

Key Points: 
  • PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution).
  • The conference was held from September 6-8, 2023 in Las Vegas, NV.
  • Taken together, these data suggest that to achieve pain freedom with Elyxyb, fewer patients need to be treated and may have less likelihood of being harmed, than with ubrogepant or rimegepant.
  • Elyxyb is a remarkable addition to armamentarium for treatment of acute migraine.” said Stewart Tepper, MD, The New England Institute for Neurology and Headache, Stamford, CT, USA.

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Retrieved on: 
Friday, June 30, 2023

Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks.

Key Points: 
  • Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks.
  • Four abstracts from the third interim analysis of the PEARL study will be presented at the 9th European Academy of Neurology (EAN) Congress in Budapest, Hungary.
  • 968 patients (87.3% female) out of the 1140 study patients had available data to include in the 3rd interim analysis.
  • The mean monthly duration of remaining migraine attacks and monthly mean score for peak headache severity of remaining migraine attacks decreased at 12 months after fremanezumab initiation.

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

Retrieved on: 
Thursday, June 15, 2023

Results showed that treatment with AJOVY was associated with statistically significant reductions in migraine days as well as reductions in symptoms of depression (HAMD-17 and PHQ-9 scores) over 12 weeks in patients with migraine and major depressive disorder.

Key Points: 
  • Results showed that treatment with AJOVY was associated with statistically significant reductions in migraine days as well as reductions in symptoms of depression (HAMD-17 and PHQ-9 scores) over 12 weeks in patients with migraine and major depressive disorder.
  • The 2023 AHS Annual Scientific Meeting is being offered both in-person and virtually.
  • The study aimed to evaluate the efficacy and safety of AJOVY in adults with migraine and major depressive disorder.
  • Secondary efficacy endpoints included the proportion of patients achieving ≥50% reduction in major depressive disorder from baseline to Week 12.

Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)

Retrieved on: 
Monday, May 22, 2023

CHATHAM, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers. Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center, will serve as principal investigator for the study.

Key Points: 
  • Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center, will serve as principal investigator for the study.
  • “Collaborating with Professor Maassen van den Brink is an exciting opportunity to learn about the potential for TNX-1900 for treating migraine, facial pain and other related conditions,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • Oxytocin represents a potential new therapeutic option, targeting a pathway in migraine that is distinct from the recently available CGRP inhibitor migraine treatment drug class.”
    In February 2023, Tonix initiated enrollment in its Phase 2 PREVENTION study of TNX-1900 for chronic migraine.
  • The Company expects topline results in the fourth quarter of this year.

Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications

Retrieved on: 
Wednesday, April 26, 2023

SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential drug-drug interactions (DDIs) between Trudhesa® (dihydroergotamine [DHE] mesylate) nasal spray (0.725 mg per spray) and orally administered gepant medications.

Key Points: 
  • The analysis being presented suggests that no DDIs of clinical concern are theoretically predicted if Trudhesa and gepants are co-administered within recommended clinical doses.
  • Additionally, while first-pass metabolism may limit the bioavailability of orally administered drugs, since Trudhesa is administered via the upper nasal space, it bypasses the gastrointestinal (GI) and hepatic first-pass metabolism.
  • “These data suggest that Trudhesa used with some oral CGRP (calcitonin gene-related peptide) acute medications may be a safe option that warrants further study.
  • These analyses shed some light on the potential safety profile of Trudhesa when prescribed concomitantly with certain other widely used migraine therapeutics,” said Sheena Aurora, M.D., Vice President Medical Affairs, Impel Pharmaceuticals.

Royalty Pharma Raises Full Year 2023 Guidance

Retrieved on: 
Wednesday, March 15, 2023

As a result, Royalty Pharma is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2,850 million and $2,950 million (from between $2,375 million and $2,475 million), excluding transactions announced subsequent to the date of this release.

Key Points: 
  • As a result, Royalty Pharma is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2,850 million and $2,950 million (from between $2,375 million and $2,475 million), excluding transactions announced subsequent to the date of this release.
  • “We are pleased that Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patients,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.
  • Royalty Pharma today provides this guidance based on its most up-to-date view on its prospects.
  • Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the company.

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

Retrieved on: 
Friday, March 10, 2023

The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo.

Key Points: 
  • The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo.
  • “The FDA approval of ZAVZPRET marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications,” said Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer.
  • “ZAVZPRET underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives.
  • “Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works.